1. Scale and Economics: What AI Actually Costs and What It Might Deliver The pharmaceutical industry’s standard development timeline averages […]

The expiration of primary patents on high-value therapeutics, frequently termed the patent cliff, creates a predictable revenue vacuum for innovators.

Patent opposition is where pharma IP stops being administrative paperwork and starts functioning as competitive strategy. A single successful opposition

There is a persistent myth in the pharmaceutical industry that generic drug development is a reduced-complexity, paint-by-numbers exercise. You take

1. Why Generic Defense Requires a Ten-Year Lead Time The time to begin planning for generic competition is the day

The pharmaceutical company that treats its patent portfolio as a legal filing system is the one that gets ambushed at

Section 1: The Deal Beneath the Deal: Why Licensing Structure Reveals Strategic Intent A pharmaceutical patent licensing agreement is not

I. Executive Summary and Key Takeaways Patient advocacy groups (PAGs) have crossed a threshold. They are no longer peripheral voices